Rhythm Pharmaceuticals, Inc.
RYTM
Rank in Stocks
#3013
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Share Price
$88.37
Last synced: 2026-10-19
Market Cap
$6.08B
Change (1 day)
2.55%
Change (1 year)
-21.37%
Country
US
Trade Rhythm Pharmaceuticals, Inc. (RYTM)
Category
Healthcare
P/E ratio for Rhythm Pharmaceuticals, Inc. (RYTM)
P/E ratio as of October 2026 TTM: -27.88
According to Rhythm Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -27.88. At the end of 2023 the company had a P/E ratio of -14.36.
P/E ratio history for Rhythm Pharmaceuticals, Inc. from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -27.88 | 112.83% |
| 2024 | -13.10 | -8.73% |
| 2023 | -14.36 | 71.31% |
| 2022 | -8.38 | 17.84% |
| 2021 | -7.11 | -29.14% |
| 2020 | -10.04 | 61.55% |
| 2019 | -6.21 | -44.80% |
| 2018 | -11.25 | -51.17% |
| 2017 | -23.04 | 18.79% |
| 2016 | -19.40 | -29.78% |
| 2015 | -27.62 | -41.36% |
| 2014 | -47.11 | -33.05% |
| 2013 | -70.37 | -15.40% |
| 2012 | -83.18 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -203.23% |
US
|
|
| -28.36 | 1.71% |
US
|
|
| -24.57 | -11.89% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -208.78% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.